menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Orphan Drug Act: 25 Years of Treating Rare Illnesses

close
Orphan Drug Act: 25 Years of Treating Rare Illnesses
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Not all drug companies are in pursuit of billion-dollar blockbuster drugs taken by millions of Americans. In fact, there are drugs treating rare conditions that wouldn't be sold on the market if not for a landmark piece of legislation known as the Orphan Drug Act, now 25 years old. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about the silver anniversary of the Orphan Drug Act, its benefits and its future potential.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Not all drug companies are in pursuit of billion-dollar blockbuster drugs taken by millions of Americans. In fact, there are drugs treating rare conditions that wouldn't be sold on the market if not for a landmark piece of legislation known as the Orphan Drug Act, now 25 years old. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about the silver anniversary of the Orphan Drug Act, its benefits and its future potential.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 6/5/20